Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Coverage initiated by StockNews.com analysts

StockNews.com equity research analysts have begun covering stocks of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get Appraisal) in a note released Saturday to investors. The company has placed a “holding” rating on the stock.

FMS has been the subject of several other reports. DZ Bank reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 research report. JPMorgan Chase & Co. cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report Monday, August 1. Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a Wednesday research note June 22. Berenberg Bank lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday 10 research note. august. Finally, Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and raised its share price target by $30.30. at $33.70 in a Monday, June 27 report. One equity research analyst has assigned the stock a sell rating, eight have issued a hold rating and three have assigned the stock a buy rating. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Hold” and a consensus target price of $45.83.

Fresenius Medical Care AG & Co. KGaA trades down 4.4%

FMS opened at $14.39 on Friday. The stock has a market capitalization of $8.43 billion, a P/E ratio of 9.17, a P/E/G ratio of 0.77 and a beta of 1.03. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $14.16 and a 12-month high of $36.08. The company’s fifty-day simple moving average is $18.35 and its 200-day simple moving average is $25.81. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt ratio of 0.47.

Institutional trading of Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently increased or reduced their stake in FMS. Tcwp LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the first quarter for a value of approximately $44,000. SRS Capital Advisors Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company worth $52,000 after buying 409 additional shares in the last quarter. Creative Financial Designs Inc. ADV bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter for a value of approximately $67,000. GHP Investment Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter for a value of approximately $72,000. Finally, Signaturefd LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company worth $74,000 after purchasing an additional 458 shares in the last quarter. Hedge funds and other institutional investors own 5.59% of the company’s shares.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Fresenius Medical Care AG & Co. KGaA didn’t make the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here